Given the fact that gene amplification has not constituted an avenue for precision medicine targeting for any gene in any cancer type yet, and the fact that RAC1-amp (2% cases) and A159V mutation (1.2% cases) in total (~3.2% cases) account for more than 32,960 HNSCC patients worldwide [1.03 million new cases/year by 2030 [46]], the precision targeting of this notable subset of patients would be clinically relevant and meaningful. Here, RAC1 is linked to cancer.